The San Francisco-based firm will use the proceeds to accelerate commercialization of its Intellisep rapid sepsis test.

The governmental funding will support the company's plans for a 1,350 participant trial that aims to further validate its protein-based cancer early detection assay.

NowDx's First to Know Syphilis Test received FDA authorization in August, making it the first over-the-counter syphilis test to be authorized by the agency.

Deck: Xgenera has also closed a round of seed financing worth £500,000 and commenced a partnership with YouSeq, a UK technology firm.

The Maryland-based firm reported in a recent proof-of-concept study that It used protease biomarkers to identify patients with lower respiratory tract infections.